Biohaven says FDA placed partial clinical hold on BHV-7000 enrollment
Biohaven Ltd. said the FDA put a partial clinical hold on BHV-7000 enrollment after a rodent metabolite finding. The company also said it shared related data with SK Biopharma under a licensing deal that could total $795M plus royalties.